Shots:
- ImmVira dosed the first pt with NMIBC in a P-II study evaluating MVR-T3011. Based on approval discussion with the US FDA the company aims to confirm the recommended P-II dose (RP2D) of intravesical administered MVR-T3011 and assess its anti-tumor efficacy in BCG-unresponsive NMIBC pts
- MVR-T3011 preliminary data presented at ESMO’24 showed a high CRR of over 80% at the 2×10⁹ PFU dose cohort in high-risk BCG-failed NMIBC pts. Updated data from an expanded cohort of 16 evaluable pts with papillary diseases showed sustained efficacy, with a Kaplan-Meier estimated 3mos. RFS of over 80%
- MVR-T3011 is an oncolytic immunotx. that integrate PD-1 Ab and IL-12 genes into its genome, enhancing immune responses within the tumor microenvironment
Ref: Prnewswire | Image: Prnewswire | Press Release
Related News:- ImmunityBio’s Anktiva Receives the US FDA’s Approval to Treat Non-Muscle Invasive Bladder Cancer (NMIBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
